Related references
Note: Only part of the references are listed.Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen
Rikke Andersen et al.
CLINICAL CANCER RESEARCH (2016)
The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy
Jonathan T. Sockolosky et al.
ADVANCED DRUG DELIVERY REVIEWS (2015)
Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2
Eric F. Zhu et al.
CANCER CELL (2015)
Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms
Jamie B. Spangler et al.
IMMUNITY (2015)
Adoptive cell transfer as personalized immunotherapy for human cancer
Steven A. Rosenberg et al.
SCIENCE (2015)
Remote control of therapeutic T cells through a small molecule-gated chimeric receptor
Chia-Yung Wu et al.
SCIENCE (2015)
The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases
David Klatzmann et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Two Functionally Distinct Subsets of Mast Cells Discriminated By IL-2-Independent CD25 Activities
Lorenzo Deho et al.
JOURNAL OF IMMUNOLOGY (2014)
IL-2: The First Effective Immunotherapy for Human Cancer
Steven A. Rosenberg
JOURNAL OF IMMUNOLOGY (2014)
Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface
Steven M. Lewis et al.
NATURE BIOTECHNOLOGY (2014)
Synthetic control of mammalian-cell motility by engineering chemotaxis to an orthogonal bioinert chemical signal
Jason S. Park et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes
Matthias G. J. Baud et al.
SCIENCE (2014)
Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology
Michael Kalos et al.
IMMUNITY (2013)
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'
Aron M. Levin et al.
NATURE (2012)
Control of protein signaling using a computationally designed GTPase/GEF orthogonal pair
Gregory T. Kapp et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
The role of interleukin-2 during homeostasis and activation of the immune system
Onur Boyman et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Alternate States of Proteins Revealed by Detailed Energy Landscape Mapping
Michael D. Tyka et al.
JOURNAL OF MOLECULAR BIOLOGY (2011)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Computer-aided design of functional protein interactions
Daniel J. Mandell et al.
NATURE CHEMICAL BIOLOGY (2009)
B-cell CD25 expression in murine primary and secondary lymphoid tissue
S. Amu et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2006)
Generation of peptide-MHC class I complexes through UV-mediated ligand exchange
Boris Rodenko et al.
NATURE PROTOCOLS (2006)
Isolating and engineering human antibodies using yeast surface display
Ginger Chao et al.
NATURE PROTOCOLS (2006)
Structure of the quaternary complex of interleukin-2 with its α, β, and γc receptors
XQ Wang et al.
SCIENCE (2005)
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
L Gattinoni et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Protein structure prediction and analysis using the Robetta server
DE Kim et al.
NUCLEIC ACIDS RESEARCH (2004)
Compensatory energetic mechanisms mediating the assembly of signaling complexes between interleukin-2 and its α, β, and γc receptors
M Rickert et al.
JOURNAL OF MOLECULAR BIOLOGY (2004)
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells
WW Overwijk et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma:: In vivo persistence, migration, and antitumor effect of transferred T cells
C Yee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo
AB Shanafelt et al.
NATURE BIOTECHNOLOGY (2000)
Share Paper
